

RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A reappraisal and Indirect **Comparison With Vaccinated Subjects**

Gillot, Constant; FAVRESSE, Julien; Maloteau, Vincent; Dogne, Jean-Michel; Douxfils, Jonathan

Publication date: 2023

Document Version Peer reviewed version

Link to publication

Citation for pulished version (HARVARD):

Gillot, C, FAVRESSE, J, Maloteau, V, Dogne, J-M & Douxfils, J 2023, 'Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A reappraisal and Indirect Comparison With Vaccinated Subjects'.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
 You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests.

A reappraisal and Indirect Comparison With Vaccinated Subjects

Constant Gillot¹, Julien Favresse^{1,2}, Vincent Maloteau¹, Jean-Michel Dogné¹ and Jonathan Douxfils^{1,3} ¹Department of Pharmacy, Namur Research Institute for Life Sciences, University of Namur, 5000 Namur, Belgium ²Department of Laboratory Medicine, Clinique St-Luc Bouge, 5000 Namur, Belgium ³Qualiblood s.a., 5000 Namur, Belgium

INTRODUCTION

Following COVID-19 infection or vaccination, numerous antibodies are produced targeting different epitopes of the virus or the spike protein. Nevertheless, not all these antibodies are able to efficiently neutralize the virus since they can bind an epitope which is not essential for the virus entry into the cell. Therefore, the detection of neutralizing antibodies (NAbs) is of particular importance because these are the antibodies that can prevent the binding of the RBD of the S protein to the angiotensin-converting enzyme 2 (ACE2) receptor present at the surface of human cells, preventing the

METHOD

Study Population:

62 RT-PCR confirmed COVID-19 patients for 114 samples from day 1 to day 296 after symptoms onset.

In this cohort, we assessed:

- Six commercial binding assays:
 - Roche nucleocapsid (NCP) total antibody assay
 - Roche RBD total antibody assay
 - DiaSorin S1/S2 IgG assay
 - Ortho S1 IgG assay
 - Ortho S1 total antibody assay
- Two neutralizing techniques:
 - Surrogate virus neutralization test (sVNT)
 - Pseudo virus neutralization test (pVNT)

Phadia S1 IgG assay

RESULTS





Table 1

Serological assay	Roche RBD total antibody assay	Roche NCP total antibody assay	DiaSorin S1/S2 IgG assay	Ortho S1 IgG assay	Ortho S1 total antibody assay	Phadia S1 IgG assay	sVNT
Cut-off definition	Manufacturer: 0.8 U/mL	Manufacturer: 1.0 COI	Manufacturer: 15.0 U/mL	Manufacturer: 1.0 S/V	Manufacturer: 1.0 S/V	Manufacturer: 0.7 U/mL	Manufacturer: 10.0 U/mL
	Adapted: 5.9 U/mL	Adapted: 37.7 COI	Adapted: 11.4 U/mL	Adapted: 0.3 S/V	Adapted: 165.0 S/V	Adapted: 2.5 U/mL	Adapted: 16.6 U/mL
Sensitivity	97.8%	97.8%	87.6%	90.0%	98.9%	97.1%	97.8%
	(92.2%-99.7%)	(92.2%-99.7%)	(79.0% - 93.7%)	(81.9-95.3%)	(94.0%-100.0%)	(92.1% - 99.7%)	(92.3% - 99.7%)
(95% CI)	88.8%	61.8%	91.0%	93.3%	53.9%	96.6%	97.7%
	(80.3% - 94.5%)	(50.9% - 71.9%)	(83.1% - 96.0%)	(85.9% - 97.5%)	(43.0% - 64.6%)	(90.5% - 99.3%)	(92.1% - 99.7%)
Specificity	33.3%	12.5%	44.0%	41.7%	16.7%	16.0%	65.2%
	(15.6-55.3%)	(2.7%-32.4%)	(24.4% - 65.1%)	(22.1%-63.4%)	(4.7%-37.4%)	(4.5% - 36.1%)	(42.7% - 83.6%)
Specificity	52.0%	84.0%	40.0%	40.0%	84.0%	28.0%	92.0%
(95% CI)	(31.3% - 72.2%)	(63.9% - 95.5%)	(21.1% - 61.3%)	(21.1% - 61.3%)	(63.9% - 95.5%)	(12.1% - 49.4%)	(74.0% - 99.0%)

Using the cut-off provided by the manufacturers, the sensitivity did not statistically differ between the different serological assays investigated in this study (**Table 1, Figure 1**). The specificity was below 50.0% for all assays meaning that these assays generate many false positive results for the detection of NAbs. In general, serological assays targeting **total antibodies** generate **less false negative results**. This means that also **measuring both IgA and IgM permit to better evaluate the neutralizing capacity of the serum than just targeting IgG.** The sVNT test showed **the best correlation** with the pVNT technique.



CONCLUSION

The correlation between the pVNT results and the sVNT results is better than the other but the data remains very τεςτς heterogeneous. Results obtained with the infected and the vaccinated cohort suggest that there is a relationship between the development of NAbs and the time of exposure to the virus. Patients with prolonged exposure to SARS-CoV-2 had a higher NAbs titer than patients who cleared the virus earlier. These results deserve further investigations to better understand the difference in the dynamic of antibody production after COVID-19 disease and vaccination.

Concerning COVID-19 patients, from day 14 to day 291, more than **75% of the samples were positive for NAbs** (n=87/110, 79.1%). Six months post symptoms onset, the majority of the samples (n=44/52, 84.6%) were still positive for NAbs. (Figure 2 A)

This is in sharp contrast with the results we obtained 6 months post-vaccination in our cohort of healthcare workers which have received the two dose regimens of BNT162b2. In this cohort 43% (n=25/58) of the participants no longer exhibit NAbs activity 180 days after the administration of the first dose of BNT162b2.

Those who were seropositive at baseline seemed to lose their neutralizing capacity (n=7/18, 39%). (Figure 2 B)

CONTACT INFORMATION

Constant Gillot <u>Constant.gillot@unamur.be</u> + 32 (0)81 72 42 92



Days post symptoms onset